Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia

Journal of Oncology Pharmacy Practice

Volumn 12, Issue 2, 2006, Pages 105-111

  Mabasa, Vincent H ^a   Taylor, Suzanne C M ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cost effectiveness; Malignant gliomas; Temozolomide

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; LOMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANADA; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FEMALE; GLIOMA; HUMAN; MALE; MEDICAL RECORD; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; LOMUSTINE; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39049181851     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206069161     Document Type: Article

References (14)

1. Fisher PG, Buffler PA. Malignant gliomas in 2005 where to GO from here? JAMA 2005;293:615-617.
2. Greanya ED, Taylor SCM, Hu F, Barnett J, Thiessen B. Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis. J Oncol Pharm Practice 2004;10:201-209.
3. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004;100:605-611.
4. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amistà P, Gardiman M, Iuzzolino P, Turazzi S, Monfardinia S. Temozolomide in patients with glioblastoma at second relapse after first line nitrosoureaprocarbazine failure: A phase II study. Oncology 2002;63:38-41.
5. Yung WKA, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-2771.
6. Bower M, Newlands ES, Bleehan NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH. Multi-centre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother Pharmacol 1997;40:484-488.
7. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-266.
8. Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. Ann Oncol 2001;12:255-257.
9. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593.
10. Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulera F, Faggionato F, Serino D, Galli C, Andreuccetti M, Buxton N, Gagliardi R. Temozolomide as first line agent in treating high-grade gliomas: Phase II study. J Neurooncol 2004; 67: 77 - 81
11. Taylor SCM, Uyeno KT, O'Reilly SE, Murphy KC, Kapty ADK. Development of a systemic therapy costing model in a provincial oncology centre (abstract). Eur J Cancer 2000;36:S26-S26.
12. Taylor SCM, Chow L. Development of a pharmacoeconomics service in a provincial oncology program (abstract). Eur J Cancer 1997;33:S31-S31.
13. Stupp R, Dietrich PY, Ostermann Kralijevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382.
14. Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma mutliforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group (abstract 2). Proc Am Soc Clin Oncol 2004;23:1-1.